MS Patient Lifespan, Comorbidities Studied in New Research

Click here to receive MS news via e-mail

Researchers at the University of Manitoba in Canada recently conducted a study that explored the differences in lifespan and comorbidities in patients with multiple sclerosis compared to healthy individuals. The study was recently published in the journal Neurology and is entitled “Effect of comorbidity on mortality in multiple sclerosis.

MS is a progressive neurodegenerative disorder that results from the attack to the central nervous system (brain, spinal cord and optical nerves) by the body’s own immune system, causing inflammation and damage to the myelin layer that covers and protects neurons. Myelin loss leads to impairment in signal transmission along nerve fibers, affecting motor function and causing irreversible neurological disability and paralysis.

In the study, researchers analyzed 5,797 MS patients and a matched cohort of 28,807 healthy individuals of the same sex, same age and from the same region, to compare mortality rates and causes of death. The association between comorbidity status and mortality was also assessed.

The team found that MS patients lived a median of 76 years while healthy individuals lived a median of 83 years. In total, 44% of the patients died from the disease and associated complications, followed by circulatory system disorders, cancer and respiratory disease.

Researchers analyzed whether participants had other medical conditions, like diabetes, chronic lung disease, ischemic heart disease, anxiety and depression, and found that overall, the presence of other cormobidities had no impact on the lifespan of MS patients any more than it did in healthy individuals without the disease. However MS patients with other conditions, such as diabetes, had a shorter life span than those without. “Treating other conditions better may be a way of improving survival,” noted the study’s lead author Dr. Ruth Ann Marrie in a news release.

The team concluded that MS patients have double the risk of premature death when compared to individuals without the disease, with patients younger than 59 years exhibiting a three times higher risk. Within the MS population, comorbidities were found to be associated to an increased mortality risk. “Despite studies that show MS survival may be improving over time, the more than 2.5 million people affected worldwide by this disabling disease still face a risk of dying earlier, specifically those who are diagnosed younger,” concluded Dr. Marrie.

Tagged , , .

Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.
Click here to receive MS news via e-mail


  1. Maggie says:

    Ok this is not great statistics for us and I understand the truth hurts but dang.

    The team concluded that MS patients have DOUBLE the risk of premature death when compared to individuals without the disease, with patients YOUNGER THAN 59 years exhibiting a THREE TIMES higher risk. Within the MS population, comorbidities were found to be associated to an increased mortality risk

    These studies should contribute to the urgency of regenerative medicine among all patients and their doctors. I understand greed but isn’t there a line that as human beings we don’t cross. Compassion over money, COME ON!!!!!!!

    • Bettyboop says:

      Totally agree Maggie. I wonder how many realize what is really going on with these studies. Unfortunately living off of us is what keeps them in a job. Cure is not the answer, keeping people drugged up DMDs are their intentions. No wonder we do not live as long. DUH.

  2. Alejandro Arturi says:

    Hurry up people from Pharma Business! If we dye soon, you are going to have less clients soon !!!!

  3. Pina ... says:

    Pah! Mi EM se encontraba totalmente detenida con Interferón 1a durante mas de 10 años.
    Me lo negó un doctor cuando me lo iba a suministrar el estado!!
    Con que intención habrá sido, me pregunto??????

  4. Linda says:

    I’d be interested to know whether the statistics are for relapsing remitting, progressive or non-distinct? We are a complex lot.

    • Patricia Silva, PhDPatricia Silva, PhD says:

      Dear Linda, the research team did not specify in their study the type of MS, but they mention that the MS cases considered for the analysis “were defined as individuals with 3 or more hospital, physician, or prescription claims for MS.”

Leave a Comment

Your email address will not be published. Required fields are marked *